Enovis (ENOV) Competitors

$24.63 +0.04 (+0.15%)

As of 10:53 AM Eastern

ENOV vs. VAC, BLCO, STVN, IRTC, and LIVN

Should you buy Enovis stock or one of its competitors? MarketBeat compares Enovis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enovis include Marriott Vacations Worldwide (VAC), Bausch + Lomb (BLCO), Stevanato Group (STVN), iRhythm Technologies (IRTC), and LivaNova (LIVN).

How does Enovis compare to Marriott Vacations Worldwide?

Enovis (NYSE:ENOV) and Marriott Vacations Worldwide (NYSE:VAC) are related companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Enovis currently has a consensus target price of $44.50, indicating a potential upside of 80.70%. Marriott Vacations Worldwide has a consensus target price of $80.70, indicating a potential upside of 7.38%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Marriott Vacations Worldwide.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Marriott Vacations Worldwide	4 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.33

Enovis has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Marriott Vacations Worldwide has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, Marriott Vacations Worldwide had 2 more articles in the media than Enovis. MarketBeat recorded 4 mentions for Marriott Vacations Worldwide and 2 mentions for Enovis. Enovis' average media sentiment score of 0.67 beat Marriott Vacations Worldwide's score of 0.40 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marriott Vacations Worldwide	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Marriott Vacations Worldwide has a net margin of -6.72% compared to Enovis' net margin of -49.92%. Marriott Vacations Worldwide's return on equity of 11.37% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
Marriott Vacations Worldwide	-6.72%	11.37%	2.58%

98.5% of Enovis shares are owned by institutional investors. Comparatively, 89.5% of Marriott Vacations Worldwide shares are owned by institutional investors. 2.9% of Enovis shares are owned by company insiders. Comparatively, 13.3% of Marriott Vacations Worldwide shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Marriott Vacations Worldwide has higher revenue and earnings than Enovis. Marriott Vacations Worldwide is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.63	-$1.18B	-$19.88	N/A
Marriott Vacations Worldwide	$5.09B	0.51	-$308M	-$10.09	N/A

Summary

Enovis beats Marriott Vacations Worldwide on 9 of the 16 factors compared between the two stocks.

How does Enovis compare to Bausch + Lomb?

Enovis (NYSE:ENOV) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

In the previous week, Bausch + Lomb had 9 more articles in the media than Enovis. MarketBeat recorded 11 mentions for Bausch + Lomb and 2 mentions for Enovis. Enovis' average media sentiment score of 0.67 beat Bausch + Lomb's score of 0.53 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis presently has a consensus target price of $44.50, indicating a potential upside of 80.70%. Bausch + Lomb has a consensus target price of $18.08, indicating a potential upside of 13.09%. Given Enovis' stronger consensus rating and higher probable upside, equities analysts clearly believe Enovis is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Bausch + Lomb has a net margin of -4.21% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
Bausch + Lomb	-4.21%	3.60%	1.69%

Bausch + Lomb has higher revenue and earnings than Enovis. Bausch + Lomb is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.63	-$1.18B	-$19.88	N/A
Bausch + Lomb	$5.10B	1.12	-$360M	-$0.62	N/A

98.5% of Enovis shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.9% of Enovis shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enovis has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Summary

Enovis beats Bausch + Lomb on 11 of the 17 factors compared between the two stocks.

How does Enovis compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Stevanato Group has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Enovis has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, Enovis had 2 more articles in the media than Stevanato Group. MarketBeat recorded 2 mentions for Enovis and 0 mentions for Stevanato Group. Enovis' average media sentiment score of 0.67 beat Stevanato Group's score of 0.00 indicating that Enovis is being referred to more favorably in the news media.

Company	Overall Sentiment
Stevanato Group	Neutral
Enovis	Positive

Stevanato Group has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.20B	4.59	€158.21M	€0.59	30.91
Enovis	$2.25B	0.63	-$1.18B	-$19.88	N/A

Enovis has a consensus price target of $44.50, suggesting a potential upside of 80.70%. Given Enovis' stronger consensus rating and higher probable upside, analysts plainly believe Enovis is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Stevanato Group has a net margin of 11.76% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Enovis	-49.92%	10.32%	4.57%

98.5% of Enovis shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Enovis beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does Enovis compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Enovis has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

iRhythm Technologies has a net margin of -3.53% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Enovis	-49.92%	10.32%	4.57%

iRhythm Technologies currently has a consensus target price of $191.85, suggesting a potential upside of 62.99%. Enovis has a consensus target price of $44.50, suggesting a potential upside of 80.70%. Given Enovis' higher possible upside, analysts clearly believe Enovis is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

98.5% of Enovis shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, iRhythm Technologies had 6 more articles in the media than Enovis. MarketBeat recorded 8 mentions for iRhythm Technologies and 2 mentions for Enovis. Enovis' average media sentiment score of 0.67 beat iRhythm Technologies' score of 0.23 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has higher earnings, but lower revenue than Enovis. iRhythm Technologies is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.18	-$44.55M	-$0.86	N/A
Enovis	$2.25B	0.63	-$1.18B	-$19.88	N/A

Summary

Enovis beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Enovis compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

LivaNova has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Enovis has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

LivaNova has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.92	-$242.47M	$1.95	37.88
Enovis	$2.25B	0.63	-$1.18B	-$19.88	N/A

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LivaNova has a net margin of 7.48% compared to Enovis' net margin of -49.92%. LivaNova's return on equity of 16.48% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Enovis	-49.92%	10.32%	4.57%

LivaNova currently has a consensus price target of $79.38, indicating a potential upside of 7.47%. Enovis has a consensus price target of $44.50, indicating a potential upside of 80.70%. Given Enovis' stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, LivaNova had 1 more articles in the media than Enovis. MarketBeat recorded 3 mentions for LivaNova and 2 mentions for Enovis. Enovis' average media sentiment score of 0.67 beat LivaNova's score of 0.57 indicating that Enovis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enovis beats LivaNova on 9 of the 17 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	MEDICAL INFO SYS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.42B	$1.46B	$6.39B	$23.17B
Dividend Yield	N/A	N/A	2.79%	4.11%
P/E Ratio	-1.24	64.33	20.96	30.59
Price / Sales	0.63	21.84	543.44	14.31
Price / Cash	0.99	22.77	44.13	24.77
Price / Book	0.96	6.37	10.00	4.75
Net Income	-$1.18B	-$54.76M	$3.55B	$1.07B
7 Day Performance	1.27%	6.31%	4.95%	2.04%
1 Month Performance	4.13%	11.13%	1.65%	0.44%
1 Year Performance	-23.89%	1.81%	37.16%	28.34%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	4.3338 of 5 stars	$24.63 +0.2%	$44.50 +80.7%	-24.1%	$1.42B	$2.25B	N/A	7,802	Analyst Forecast
VAC Marriott Vacations Worldwide	3.1521 of 5 stars	$75.29 -2.4%	$80.60 +7.1%	+12.6%	$2.65B	$5.03B	N/A	21,100
BLCO Bausch + Lomb	4.1371 of 5 stars	$16.10 -0.5%	$18.08 +12.3%	+43.7%	$5.77B	$5.21B	N/A	13,000
STVN Stevanato Group	2.4596 of 5 stars	€18.29 +0.1%	N/A	-25.7%	€5.54B	€1.34B	31.00	6,010
IRTC iRhythm Technologies	4.2716 of 5 stars	$116.84 -3.2%	$193.38 +65.5%	-15.7%	$3.97B	$747.14M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors

ENOV vs. VAC, BLCO, STVN, IRTC, and LIVN

How does Enovis compare to Marriott Vacations Worldwide?

Summary

How does Enovis compare to Bausch + Lomb?

Summary

How does Enovis compare to Stevanato Group?

Summary

How does Enovis compare to iRhythm Technologies?

Summary

How does Enovis compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enovis (ENOV) Competitors

ENOV vs. VAC, BLCO, STVN, IRTC, and LIVN

How does Enovis compare to Marriott Vacations Worldwide?

Do analysts rate ENOV or VAC?

Which has more volatility & risk, ENOV or VAC?

Does the media prefer ENOV or VAC?

Is ENOV or VAC more profitable?

Do institutionals and insiders have more ownership in ENOV or VAC?

Which has preferable earnings & valuation, ENOV or VAC?

Summary

How does Enovis compare to Bausch + Lomb?

Does the media prefer ENOV or BLCO?

Do analysts prefer ENOV or BLCO?

Is ENOV or BLCO more profitable?

Which has better valuation & earnings, ENOV or BLCO?

Do insiders and institutionals have more ownership in ENOV or BLCO?

Which has more volatility and risk, ENOV or BLCO?

Summary

How does Enovis compare to Stevanato Group?

Which has more risk and volatility, STVN or ENOV?

Does the media favor STVN or ENOV?

Which has preferable valuation & earnings, STVN or ENOV?

Do analysts recommend STVN or ENOV?

Is STVN or ENOV more profitable?

Do institutionals & insiders have more ownership in STVN or ENOV?

Summary

How does Enovis compare to iRhythm Technologies?

Which has more risk & volatility, IRTC or ENOV?

Is IRTC or ENOV more profitable?

Do analysts recommend IRTC or ENOV?

Do institutionals and insiders have more ownership in IRTC or ENOV?

Does the media favor IRTC or ENOV?

Which has stronger earnings and valuation, IRTC or ENOV?

Summary

How does Enovis compare to LivaNova?

Which has more risk and volatility, LIVN or ENOV?

Which has higher earnings and valuation, LIVN or ENOV?

Do institutionals & insiders believe in LIVN or ENOV?

Is LIVN or ENOV more profitable?

Do analysts prefer LIVN or ENOV?

Does the media refer more to LIVN or ENOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENOV vs. The Competition

Enovis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools